Published June 20, 2022 | Version 1.0.0
Dataset Open

Virtual screening on SARS-CoV-2 Nsp14_testing of 5474 hits in a Nsp14 biochemical assay and an A549-hACE2 SARS-CoV-2 infected cells

  • 1. Janssen Pharmaceutica NV



This report describes the most relevant results of virtually screening the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 Nsp14 and confirmation of potential hits in a SARS-CoV-2 Nsp10/Nsp14 biochemical exonuclease assay and in a A549-hACE2 cell-based anti-SARS-CoV-2 assay.